Proscia

Good morning from #SOT2025 & ToxExpo! 🌞 We're loving it here in sunny Orlando showing you how our Concentriq LS #digitalpathology platform is helping preclinical teams to: ➡️ Instantly collaborate between CROs and sponsors with real-time data sharing. ➡️ Unlock patterns linked to drug safety and efficacy with AI-powered toxicity assessments. ➡️ Simplify compliance with built-in audit logs and change tracking to support GLP study requirements with ease. Visit Booth 1312 to see for yourself, or book a meeting here: bit.ly/41rBg8I

We couldn't have said it better ourselves, Svenja Lippok! Driving the DICOM standard forward is key to accelerating the scaled adoption of #digitalpathology and AI.

At Proscia, our vision for AI extends beyond image analysis applications. We're integrating intelligence seamlessly into routine workflows, working invisibly to enhance and automate the daily operations supporting image reviews. The latest release represents a significant step toward making Concentriq AP* intelligent to the core, with AI-native enhancements that address real workflow challenges faced by anatomic laboratories. Here's what's new: 1️⃣ AI-powered multi-slide auto-alignment: Instantly align serial sections with exceptional precision; synchronized panning, zooming, and rotation 2️⃣ Enhanced interoperability and global accessibility: Meeting the evolving needs of enterprise labs as they grow and scale 3️⃣ Workflow efficiency boosters: Streamlined slide access and improved annotation visibility to reduce clicks and accelerate reviews View our most recent blog post here to learn more: bit.ly/422MeCV *Concentriq AP is For Research Use Only. Not for use in diagnostic procedures.

We 💙 our customers. That's why Jason Maloney and team are raising the bar when it comes to delivering a world-class customer experience—one that ensures the humans using our software realize its full value in all they do.

On March 20th, join our CEO David West and our life sciences product leader Edaeni Hamid, PhD for an exclusive webinar on our evolving enterprise pathology platform, AI, and RWD solutions. Register today: https://bit.ly/3Fxi6qr You'll discover how to: ➡️ Discover and develop the next novel therapies with our expanded product suite ➡️ Realize the full potential of Concentriq LS through live demos, best practices, and a Q&A session with our team ➡️ Accelerate AI model development with multimodal #pathology RWD As science and technology advance, so do we—enabling pharmaceutical companies, CROs, and biotechs to deliver the future of precision medicine.

Georgia Tech College of Engineering has named our Co-founder and Chief Strategy Officer Nathan Buchbinder to its Council of Outstanding Young Engineering Alumni. Nathan, who received a master’s degree in biomedical innovation and development, was recognized at a ceremony over the weekend. Congratulations, Nathan! Read the press release: https://bit.ly/3Dt96Cd

This #InternationalWomensDay, we celebrate the women of the #pathology community who inspire us every day. Below, meet pathology pioneers Dr. McGill, Dr. Hart, and Dr. Abbott, whose stories remind us that resilience shapes science and medicine. #IWD25

When we started Proscia, we thought everyone had it wrong. Pathology did not need to move from microscope to monitor. The cornerstone of the $8T healthcare market (incl $250B+ in oncology) that powered the last century of medicine was fundamentally not wired for the next century. Healthcare needed it's richest data modality to reimagine the way we develop therapies and get them to patients. Over the past 3 years, Proscia has had a front-row seat to advances in treatments. Biopharmas investing billions in immunotherapies, ADCs, and beyond are offering patients new hope—but the success of these treatments hinges on pathology. Advanced therapies need advanced diagnostics. Without change, it means: 1. More failed drugs and clinical trials. 2. Patients missing out on life-saving treatments. 3. Pathology sidelined in the next generation of medicine. Proscia exists to rewire pathology for precision medicine. I've never been more optimistic that this can happen. Nearly every major lab and health system is going digital, or already has in the last 2 years. Over 22,000 cases are read on our software per day. And pharma is investing aggressively in biomarkers & companion diagnostics built on this modality, now with a clear path to the clinic. As we start 2025, we're outlining our vision for the next 5 years of medicine. Read our latest piece, "Rewiring Pathology for Precision Medicine", on what we believe the future holds if we're successful. https://lnkd.in/ekXadqZU Thank you to Ashley Faber Sydney Fenkell Nathan Buchbinder and others who helped contribute to this!

Last week our CSO Nathan Buchbinder joined industry leaders at Philadelphia Alliance for Capital and Technologies (PACT)’s Healthcare Exchange Symposium. In case you missed it - here are a few key takeaways. ⬇️

As #2025SOT approaches, we’re wondering what’s top of mind for your preclinical team. Visit us in booth 1312 in Orlando to discover how we are transforming toxicologic pathology with Concentriq LS by enhancing productivity, collaboration, and confidence in preclinical studies.